Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Toripalimab · Surufatinib · Chemoradiotherapy · Limited-stage Small Cell Lung Cancer (LS-SCLC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Hui Liu, MD) · liuhuisysucc@126.com · +86-020-87343031

Study leads

Hui Liu, Professor
Principal Investigator
Sun yat-sen universtiy cancer center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Toripalimab Combined With Definitive CCRT for LACC Patients

Cervical Cancer · Chemoradiotherapy · Immunotherapy

Abroad (travel likely)Recruiting

Shanghai, China

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Xi'an, China · Xi'an, China

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma · Lung Cancer · Oligometastasis

Abroad (travel likely)Recruiting

Beijing, China

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Abroad (travel likely)RecruitingPHASE3

Goodyear, United States · Tucson, United States